Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

964
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
964
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

733
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
733
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

822
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
822
Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

932
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
932

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Complex Aortic Plaques and Polycythemia Vera Presenting as Blue Toe Syndrome Without Peripheral Arterial Disease.

JACC. Case reports·2026
Same author

A Novel Measurement of Percutaneous Left Atrial Appendage Occlusion Device Peri-Device Leak Using Major and Minor Axes of a Three-Dimensional Vena Contracta Area.

Echocardiography (Mount Kisco, N.Y.)·2025
Same author

Effect of Medical Therapy on Reducing the Risk of Pacing-Induced Cardiomyopathy.

Journal of the American Heart Association·2025
Same author

Atherogenic dyslipidemia and incident cardiovascular events in high-risk hypertension.

Progress in cardiovascular diseases·2025
Same author

Clinical management after surgical left atrial appendage exclusion.

Journal of cardiothoracic surgery·2025
Same author

Effects of Aligning Residency Note Templates with CMS Evaluation and Management Documentation Requirements.

Applied clinical informatics·2024
Same journal

Robotic Magnetic Navigation Versus Manual Catheter Ablation for Premature Ventricular Contractions: A Single-center Retrospective Cohort Study.

The Journal of innovations in cardiac rhythm management·2026
Same journal

Three Empty Bottles and a Wide QRS: Rapid Alkalinization Rescue in Propafenone Overdose.

The Journal of innovations in cardiac rhythm management·2026
Same journal

Left Bundle Branch Tachycardia: A Nightmare Confluence of Tachycardia and Bradycardia.

The Journal of innovations in cardiac rhythm management·2026
Same journal

Letter from the Editor in Chief.

The Journal of innovations in cardiac rhythm management·2026
Same journal

Right Ventricular Implantation of an Aveir™ AR Device for Bradycardia in a 90-Year-Old Woman with Atrial Fibrillation and Small Right Ventricular Dimensions.

The Journal of innovations in cardiac rhythm management·2026
Same journal

An Unusual Genetic Variant of Long QT Syndrome with Late Presentation in the Sixth Decade.

The Journal of innovations in cardiac rhythm management·2026
查看所有相关文章

相关实验视频

Updated: Jun 21, 2025

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.2K

患有正常运行的心脏起器的患者的弗莱卡因毒性.

Sneha Chebrolu1, Jonathan Mayl2, Prashant Bhave2

  • 1Department of Internal Medicine, Wake Forest Baptist Health, Winston-Salem, NC, USA.

The Journal of innovations in cardiac rhythm management
|July 16, 2024
PubMed
概括
此摘要是机器生成的。

通过广泛的QRS复合体识别的flecainide毒性,可以发生在带有起器的患者身上. 在一个案例研究中,调整心脏起器模式 (DDD到VVI) 解决了心跳动和改善了心电图.

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 弗莱凯尼德是一种C类抗失常药物,具有使用依赖性,这意味着其有效性在心率较高时增加.
  • 弗莱卡因的毒性特征在于心电图 (ECG) 上呈现出广泛的QRS复合体.
  • 患有结构性心脏病和急性损伤的患者有较高的风险发生弗莱卡因毒性.
关键词:
抗心律失常的 抗心律失常的这是一个ECGECGECGECGECG.弗莱卡尼德的毒性起器是一种心脏起器.使用依赖性使用依赖性腹腔动脉节奏是什么意思

更多相关视频

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.5K
Translational Rabbit Model of Chronic Cardiac Pacing
06:14

Translational Rabbit Model of Chronic Cardiac Pacing

Published on: January 6, 2023

2.5K

相关实验视频

Last Updated: Jun 21, 2025

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.2K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.5K
Translational Rabbit Model of Chronic Cardiac Pacing
06:14

Translational Rabbit Model of Chronic Cardiac Pacing

Published on: January 6, 2023

2.5K